Patents by Inventor Melanie R. Mark
Melanie R. Mark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130331553Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.Type: ApplicationFiled: January 4, 2013Publication date: December 12, 2013Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Patent number: 8349329Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.Type: GrantFiled: March 3, 2010Date of Patent: January 8, 2013Assignee: Genetech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Publication number: 20100234576Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.Type: ApplicationFiled: March 3, 2010Publication date: September 16, 2010Applicant: GENENTECH, INC.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Patent number: 7696327Abstract: The invention relates to the identification and isolation of DNAs encoding the human Toll proteins PR0285, PR0286, and PR0358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PR0285, or PR0286, or PR0358 Toll protein.Type: GrantFiled: October 7, 1998Date of Patent: April 13, 2010Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
-
Publication number: 20040234498Abstract: A tumor necrosis factor homolog, identified as DNA19355, is provided. DNA19355 polypeptide has apoptotic activity in mammalian cancer cells and may be involved in proinflammatory responses. Nucleic acid molecules encoding DNA19355, chimeric molecules and antibodies to DNA19355 are also provided.Type: ApplicationFiled: November 14, 2003Publication date: November 25, 2004Applicant: Genentech, Inc.Inventors: Avi J. Ashkenazi, Kevin P. Baker, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Scot A. Marsters, Robert M. Pitti
-
Publication number: 20030204072Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.Type: ApplicationFiled: January 25, 1999Publication date: October 30, 2003Inventors: PAUL J. GODOWSKI, MELANIE R. MARK, DAVID T. SCADDEN, KEVIN P. BAKER, WILL F. BARON
-
Publication number: 20020147325Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.Type: ApplicationFiled: December 30, 1998Publication date: October 10, 2002Inventors: PAUL J. GODOWSKI, MELANIE R. MARK, DAVID T. SCADDEN, KEVIN P. BAKER, WILL F. BARON
-
Publication number: 20020146389Abstract: A tumor necrosis factor homolog, identified as DNA19355, is provided. DNA19355 polypeptide has apoptotic activity in mammalian cancer cells and may be involved in proinflammatory responses. Nucleic acid molecules encoding DNA19355, chimeric molecules and antibodies to DNA19355 are also provided.Type: ApplicationFiled: February 22, 2002Publication date: October 10, 2002Applicant: Genentech, Inc.Inventors: Avi J. Ashkenazi, Kevin P. Baker, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Scot A. Marsters, Robert M. Pitti
-
Publication number: 20020137113Abstract: An assay for measuring activation (i.e., autophosphorylation) of a tyrosine kinase receptor of interest is disclosed.Type: ApplicationFiled: August 8, 2001Publication date: September 26, 2002Applicant: Genentech, Inc.Inventors: Paul J. Godowski, Melanie R. Mark, Michael Daniel Sadick, Wai Lee Tan Wong
-
Patent number: 6287784Abstract: An assay for measuring activation (i.e., autophosphorylation) of a tyrosine kinase receptor of interest is disclosed. (a) A first solid phase is coated with a substantially homogeneous population of cells so that the cells adhere to the first solid phase. The cells have either an endogenous tyrosine kinase receptor or have been transformed with DNA encoding a receptor or “receptor construct” and the DNA has been expressed so that the receptor or receptor construct is presented in the cell membranes of the cells. (b) A ligand is then added to the solid phase having the adhering cells, such that the tyrosine kinase receptor is exposed to the ligand. (c) Following exposure to the ligand, the adherent cells are solubilized, thereby releasing cell lysate. (d) A second solid phase is coated with a capture agent which binds specifically to the tyrosine kinase receptor, or, in the case of a receptor construct, to the flag polypeptide.Type: GrantFiled: October 13, 1999Date of Patent: September 11, 2001Assignee: Genentech, Inc.Inventors: Paul J. Godowski, Melanie R. Mark, Michael Daniel Sadick, Wai Lee Tan Wong
-
Patent number: 6255068Abstract: An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides variant gas6 polypeptides, compositions comprising variant gas6 polypeptides, nucleic acids encoding variant gas6 polypeptides, vectors comprising those nucleic acids and host cells comprising those vectors. The present invention is further directed to methods for making variant gas6 polypeptides.Type: GrantFiled: May 31, 1995Date of Patent: July 3, 2001Assignee: Genentech, Inc.Inventors: Paul J. Godowski, R. Glenn Hammonds, Melanie R. Mark
-
Patent number: 6211142Abstract: An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides compositions comprising gas6 polypeptides wherein the gas6 polypeptides are present in an amount effective for activating the Rse receptor. The present invention is further directed to articles of manufacture comprising gas6 polypeptides such as kits and containers containing gas6 polypeptide compositions and gas6 polypeptide In a liposome or adsorbed to a membrane.Type: GrantFiled: March 10, 1995Date of Patent: April 3, 2001Assignee: Genentech, Inc.Inventors: R. Glenn Hammonds, Paul J. Godowski, Melanie R. Mark
-
Patent number: 6169070Abstract: The translation product of the growth arrest-specific gene 6 (gas6) has been identified as an activator of the Mer receptor protein tyrosine kinase. The invention accordingly provides methods of activating Mer receptor in cells expressing it by exposing them to exogenous gas6 polypeptides. Also provided are methods of enhancing the growth, differentiation, or survival of such cells using gas6 polypeptides.Type: GrantFiled: April 17, 1996Date of Patent: January 2, 2001Assignee: Genentech, Inc.Inventors: Jian Chen, R. Glenn Hammonds, Paul J. Godowski, Melanie R. Mark, Jennie P. Mather, Ronghao Li
-
Patent number: 6096527Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.Type: GrantFiled: May 22, 1995Date of Patent: August 1, 2000Inventors: Paul J. Godowski, Melanie R. Mark, David T. Scadden
-
Patent number: 6025145Abstract: An assay for measuring activation (i.e., autophosphorylation) of a tyrosine kinase receptor of interest is disclosed. a) A first solid phase is coated with a substantially homogeneous population of cells so that the cells adhere to the first solid phase. The cells have either an endogenous tyrosine kinase receptor or have been transformed with DNA encoding a receptor or "receptor construct" and the DNA has been expressed so that the receptor or receptor construct is presented in the cell membranes of the cells. b) A ligand is then added to the solid phase having the adhering cells, such that the tyrosine kinase receptor is exposed to the ligand. c) Following exposure to the ligand, the adherent cells are solubilized, thereby releasing cell lysate. d) A second solid phase is coated with a capture agent which binds specifically to the tyrosine kinase receptor, or, in the case of a receptor construct to the flag polypeptide.Type: GrantFiled: January 20, 1995Date of Patent: February 15, 2000Assignee: Genentech, Inc.Inventors: Paul J. Godowski, Melanie R. Mark, Michael Daniel Sadick, Wai Lee Tan Wong
-
Patent number: 6001621Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.Type: GrantFiled: December 20, 1993Date of Patent: December 14, 1999Assignees: Genetech, Inc., New England Deaconess (NED) HospitalInventors: Paul J. Godowski, Melanie R. Mark, David T. Scadden
-
Patent number: 5955420Abstract: An activator of the Rse receptor protein tyrosine kinase has been identified which is encoded by growth arrest-specific gene 6 (gas6). Accordingly, the present invention provides a method of activating the Rse receptor by exposing a cell comprising the Rse receptor to exogenous gas6 polypeptide. Moreover, the present invention is directed to a method for enhancing the survival, proliferation or differentiation of a cell comprising a Rse receptor by exposing the cell to exogenous gas6 polypeptide. The types of cells which can be treated according to the method include glial cells such as Schwann cells.Type: GrantFiled: May 10, 1995Date of Patent: September 21, 1999Assignee: Genentech, Inc.Inventors: Jian Chen, R. Glenn Hammonds, Paul J. Godowski, Melanie R. Mark, Jennie P. Mather, Ronghao Li
-
Patent number: 5914237Abstract: An assay for measuring activation (i.e., autophosphorylation) of a tyrosine kinase receptor of interest is disclosed.(a) A first solid phase is coated with a substantially homogeneous population of cells so that the cells adhere to the first solid phase. The cells have either an endogenous tyrosine kinase receptor or have been transformed with DNA encoding a receptor or "receptor construct" and the DNA has been expressed so that the receptor or receptor construct is presented in the cell membranes of the cells.(b) A ligand is then added to the solid phase having the adhering cells, such that the tyrosine kinase receptor is exposed to the ligand.(c) Following exposure to the ligand, the adherent cells are solubilized, thereby releasing cell lysate.(d) A second solid phase is coated with a capture agent which binds specifically to the tyrosine kinase receptor, or, in the case of a receptor construct, to the flag polypeptide.Type: GrantFiled: May 15, 1995Date of Patent: June 22, 1999Assignee: Genentech IncorporatedInventors: Paul J. Godowski, Melanie R. Mark, Michael D. Sadick, Wai Lee Tan Wong
-
Patent number: 5891650Abstract: An assay for measuring activation (i.e., autophosphorylation) of a tyrosine kinase receptor of interest is disclosed.(a) A first solid phase is coated with a substantially homogeneous population of cells so that the cells adhere to the first solid phase. The cells have either an endogenous tyrosine kinase receptor or have been transformed with DNA encoding a receptor or "receptor construct" and the DNA has been expressed so that the receptor or receptor construct is presented in the cell membranes of the cells.(b) A ligand is then added to the solid phase having the adhering cells, such that the tyrosine kinase receptor is exposed to the ligand.(c) Following exposure to the ligand, the adherent cells are solubilized, thereby releasing cell lysate.(d) A second solid phase is coated with a capture agent which binds specifically to the tyrosine kinase receptor, or, in the case of a receptor construct, to the flag polypeptide.Type: GrantFiled: May 15, 1995Date of Patent: April 6, 1999Assignee: Genentech IncorporatedInventors: Paul J. Godowski, Melanie R. Mark, Michael D. Sadick, David L. Shelton, Wai Lee Tan Wong
-
Patent number: 5879910Abstract: The invention concerns hepatocyte growth factor (HGF) variants that compise an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF.Type: GrantFiled: February 9, 1994Date of Patent: March 9, 1999Assignee: Genetech, Inc.Inventors: Paul J. Godowski, Natalie A. Lokker, Melanie R. Mark